MEP1908A - Gabaksadol za liječenje depresije i drugih afektivnih poremećaja - Google Patents

Gabaksadol za liječenje depresije i drugih afektivnih poremećaja

Info

Publication number
MEP1908A
MEP1908A MEP-19/08A MEP1908A MEP1908A ME P1908 A MEP1908 A ME P1908A ME P1908 A MEP1908 A ME P1908A ME P1908 A MEP1908 A ME P1908A
Authority
ME
Montenegro
Prior art keywords
gaboxadol
treating depression
affective disorders
pharmaceutical composition
relates
Prior art date
Application number
MEP-19/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Connie Sanchez
Bjarke Ebert
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58707228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP1908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Priority claimed from PCT/DK2004/000459 external-priority patent/WO2004112786A2/en
Publication of MEP1908A publication Critical patent/MEP1908A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-19/08A 2003-06-25 2004-06-25 Gabaksadol za liječenje depresije i drugih afektivnih poremećaja MEP1908A (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300956 2003-06-25
DKPA200400016 2004-01-07
PCT/DK2004/000459 WO2004112786A2 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Publications (1)

Publication Number Publication Date
MEP1908A true MEP1908A (xx) 2010-02-10

Family

ID=58707228

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-19/08A MEP1908A (xx) 2003-06-25 2004-06-25 Gabaksadol za liječenje depresije i drugih afektivnih poremećaja
MEP-2008-19A ME00030B (me) 2003-06-25 2004-06-25 GABOKSADOL ZA LEČENJE DEPRESIJE l DRUGIH AFEKTIVNIH POREMEĆAJA

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-19A ME00030B (me) 2003-06-25 2004-06-25 GABOKSADOL ZA LEČENJE DEPRESIJE l DRUGIH AFEKTIVNIH POREMEĆAJA

Country Status (10)

Country Link
KR (1) KR20060025192A (xx)
AR (1) AR047550A1 (xx)
CA (2) CA2692334A1 (xx)
CL (2) CL2004001607A1 (xx)
EA (1) EA200600101A1 (xx)
IS (1) IS8138A (xx)
ME (2) MEP1908A (xx)
NO (1) NO20060229L (xx)
RS (1) RS20050911A (xx)
TW (1) TW200509918A (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3883566A4 (en) 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR REDUCE RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
KR20060025192A (ko) 2006-03-20
AR047550A1 (es) 2006-01-25
CL2004001607A1 (es) 2005-05-27
CL2010000166A1 (es) 2010-07-02
CA2692334A1 (en) 2004-12-29
CA2529805A1 (en) 2004-12-29
RS20050911A (sr) 2007-08-03
NO20060229L (no) 2006-01-16
TW200509918A (en) 2005-03-16
IS8138A (is) 2005-11-21
ME00030B (me) 2010-06-10
EA200600101A1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
IL202106A0 (en) Gaboxadol for treating depression and other affective disorders
TW201713640A (en) Bruton's tyrosine kinase inhibitors
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
MX359668B (es) Derivados de retinal y metodos para su uso en el tratamiento de trastornos visuales.
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
TW200745122A (en) New compounds I
TW200736227A (en) New compounds III
MX2009013126A (es) Nuevos compuestos 892.
MX2007006042A (es) Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparacion, composiciones que las contienen y utilizacion.
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
UA90656C2 (ru) Габоксадол для лечения депрессии
MEP1908A (xx) Gabaksadol za liječenje depresije i drugih afektivnih poremećaja
WO2009158387A3 (en) Compositions, formulations, and methods for preventing and/or treating physical effects of alcohol consumption
TW200745133A (en) New compounds II
MY142082A (en) Substituted pyrroles, compositions containing them, method of manufacture and use
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
WO2009105218A3 (en) Propiophenone derivatives
CL2009001113A1 (es) Compuestos derivados de 4,5-diarilpirrol-2-carboxamida; procedimiento de preparacion de estos; composicion farmaceutica que los comprende; uso en el tratamiento y/o prevencion de trastornos psiquiatricos, dependencia a sustancias, entre otras.